Alterations in bile acid synthesis in carriers of hepatocyte nuclear factor 1α mutations

Journal of Internal Medicine

Volumn 274, Issue 3, 2013, Pages 263-272

  Ekholm, E ^a   Nilsson, R ^b   Groop, L ^a   Pramfalk, C ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cholesterol metabolism; Diabetes

Indexed keywords

ALANINE; CAMPESTEROL; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; GLUTAMINE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; ISOLEUCINE; LANOSTEROL; LATHOSTEROL; METHIONINE; SITOSTEROL; TRIACYLGLYCEROL;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BLOOD SAMPLING; BODY MASS; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPRESSION VECTOR; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; INTESTINE ABSORPTION; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; TRANSCRIPTION REGULATION;

CHOLESTEROL METABOLISM; DIABETES;

ADULT; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL; CODON; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HETEROZYGOTE; HUMANS; LIPID METABOLISM; MALE; MUTATION; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTIONAL ACTIVATION;

EID: 84881546339     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12082     Document Type: Article

References (48)

1. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508.
2. Yamagata K, Oda N, Kaisaki PJ et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384: 455-458.
3. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat 2006; 27: 854-869.
4. Bellanne-Chantelot C, Carette C, Riveline JP et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 2008; 57: 503-508.
5. Axelson M, Aly A, Sjovall J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988; 239: 324-328.
6. Axelson M, Bjorkhem I, Reihner E, Einarsson K. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 1991; 284: 216-218.
7. Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 1996; 24: 123-126.
8. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003; 44: 859-866.
9. Makishima M, Okamoto AY, Repa JJ et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.
10. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-553.
11. Shih DQ, Bussen M, Sehayek E et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001; 27: 375-382.
12. Lu TT, Makishima M, Repa JJ et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507-515.
13. Kim I, Ahn SH, Inagaki T et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007; 48: 2664-2672.
14. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49: 297-305.
15. Dawson PA, Haywood J, Craddock AL et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 2003; 278: 33920-33927.
16. Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99: 1880-1887.
17. Hruz P, Zimmermann C, Gutmann H et al. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006; 55: 395-402.
18. Richter S, Shih DQ, Pearson ER et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989-2995.
19. Wang DP, Stroup D, Marrapodi M, Crestani M, Galli G, Chiang JY. Transcriptional regulation of the human cholesterol 7 alpha-hydroxylase gene (CYP7A) in HepG2 cells. J Lipid Res 1996; 37: 1831-1841.
20. Wistuba W, Gnewuch C, Liebisch G, Schmitz G, Langmann T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol 2007; 13: 4230-4235.
21. Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem 2002; 277: 30559-30566.
22. Lou G, Li Y, Chen B et al. Functional analysis on the 5′-flanking region of human FXR gene in HepG2 cells. Gene 2007; 396: 358-368.
23. Kim HJ, Kim JY, Park YY, Choi HS. Synergistic activation of the human orphan nuclear receptor SHP gene promoter by basic helix-loop-helix protein E2A and orphan nuclear receptor SF-1. Nucleic Acids Res 2003; 31: 6860-6872.
24. Lund E, Olund J, Bjorkhem I. Determination of serum levels of unesterified lanosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 1990; 50: 723-728.
25. Lund E, Sisfontes L, Reihner E, Bjorkhem I. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 1989; 49: 165-171.
26. Lutjohann D, Bjorkhem I, Beil UF, von Bergmann K. Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 1995; 36: 1763-1773.
27. van der Hoorn J, Linden D, Lindahl U et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol 2010; 162: 1553-1563.
28. Pramfalk C, Davis MA, Eriksson M, Rudel LL, Parini P. Control of ACAT2 liver expression by HNF1. J Lipid Res 2005; 46: 1868-1876.
29. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988; 29: 1149-1155.
30. Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20-31.
31. Chen J, Cooper AD, Levy-Wilson B. Hepatocyte nuclear factor 1 binds to and transactivates the human but not the rat CYP7A1 promoter. Biochem Biophys Res Commun 1999; 260: 829-834.
32. Holt JA, Luo G, Billin AN et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-1591.
33. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Clin Prac 2009; 5: 150-159.
34. Gylling H, Miettinen TA. Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Diabetes Care 1997; 20: 90-95.
35. Lehto M, Bitzen PO, Isomaa B et al. Mutation in the HNF-4alpha gene affects insulin secretion and triglyceride metabolism. Diabetes 1999; 48: 423-425.
36. Pramfalk C, Karlsson E, Groop L et al. Control of ACAT2 liver expression by HNF4{alpha}: lesson from MODY1 patients. Arterioscler Thromb Vasc Biol 2009; 29: 1235-1241.
37. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. J Biol Chem 2002; 277: 3801-3804.
38. Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 2001; 262: 257-265.
39. Karlsson E, Groop L. [MODY-an autosomal dominant type of diabetes. Diagnosis via genetic testing results in better treatment]. Lakartidningen 2007; 104: 2600-2602.
40. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 2000; 11(Suppl. 16): S140-S143.
41. Chi YI, Frantz JD, Oh BC, Hansen L, Dhe-Paganon S, Shoelson SE. Diabetes mutations delineate an atypical POU domain in HNF-1alpha. Mol Cell 2002; 10: 1129-1137.
42. Frayling TM, Evans JC, Bulman MP et al. Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 2001; 50(Suppl. 1): S94-S100.
43. Galan M, Garcia-Herrero CM, Azriel S et al. Differential effects of HNF-1alpha mutations associated with familial young-onset diabetes on target gene regulation. Mol Med 2011; 17: 256-265.
44. Yamagata K, Yang Q, Yamamoto K et al. Mutation P291fsinsC in the transcription factor hepatocyte nuclear factor-1alpha is dominant negative. Diabetes 1998; 47: 1231-1235.
45. Vaxillaire M, Abderrahmani A, Boutin P et al. Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. J Biol Chem 1999; 274: 35639-35646.
46. Cervin C, Orho-Melander M, Ridderstrale M et al. Characterization of a naturally occurring mutation (L107I) in the HNF1 alpha (MODY3) gene. Diabetologia 2002; 45: 1703-1708.
47. Glucksmann MA, Lehto M, Tayber O et al. Novel mutations and a mutational hotspot in the MODY3 gene. Diabetes 1997; 46: 1081-1086.
48. Goodwin B, Jones SA, Price RR et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-526.